Magnetic Resonance-guided High-intensity Focused Ultrasound Treatment of Locally Advanced Pancreatic Cancer

Trial statusAvailable
Trial phaseNot listed
Trial typeExpanded Access
Biological sexAll
Age18-90
SponsorUniversity of Roma La Sapienza

About this trial

Patients with unresectable pancreatic cancer in most of cases cannot benefit from percutaneous ablation modalities, due to high risk of procedure-related complications. Ultrasound-guided high intensity focused ultrasound (HIFU) ablation has been introduced as a feasible treatment option in these patients. However, in other anatomical regions US-guided HIFU has been replaced by the more accurate MR-guided focused ultrasound (MRgFUS) ablation, but the applicability of this latter technique to the treatment of pancreatic cancer is still unexplored. The aim of this study is to explore feasibility and clinical performance of MRgFUS ablation of unresectable pancreatic cancer. Two are the main end-points: Pain palliation and local tumor control.

As compared to conventional US-guided HIFU, MRgFUS could represent a more accurate, non-invasive ablation modality even for unresectable pancreatic cancer although, to date, no cases of pancreatic MRgFUS ablation have been reported.

Eligibility criteria

Qualifiers

biopsy proven unresectable pancreatic adenocarcinoma;

unable or not willing to undergo chemo-radiation therapy

Celiac plexus alcoholization failed to control pain symptoms

Disqualifiers

contraindication to MR or general anesthesia

Trial design

Treatments tested in this trial

  • Magnetic Resonance-guided High-intensity Focused Ultrasound (MRgFUS)

Treatment groups

No treatment groups listed

Sponsors and collaborators